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Abstract
Bifurcating coronary lesions are a very common challenge in interventional cardiology because of the 
technical complexity in their treatment, the risk of side branch occlusion and an overall worse outcome 
when compared to non-bifurcating lesions.
The presence of calcifications represents further complexity due to the difficulty in device delivery and 
stent expansion as well as enhanced risk of side branch occlusion.
Rotational and orbital atherectomy, scoring and cutting balloons, coronary lithoplasty are available tools 
which have been introduced over the last three decades to overcome such issue. Nevertheless, their appli-
cation in different contexts of bifurcations presents specific caveats and the studies directed at comparing 
such techniques have never been expressly oriented in the subset of the bifurcating lesion. 
In this paper, we review these devices and their usefulness in bifurcations by analyzing consistent data 
from clinical trials, and we propose a practical algorithm for the treatment of severely calcified bifurcat-
ing lesions according to their anatomical features. (Cardiol J 2019; 26, 5: 429–437)
Key words: bifurcation, calcified lesion, plaque modification, rotational atherectomy, 
coronary lithoplasty
Introduction 
Bifurcating coronary lesions are a very com-
mon challenge for interventional cardiologists 
because of the technical complexity in their treat-
ment, a higher risk of procedural complications 
and an overall worse outcome compared to non-
bifurcating lesions [1]. The inherent difficulty of 
bifurcation percutaneous coronary intervention 
(PCI) stems from the risk that main vessel (MV) 
stenting may hamper flow in the side branch (SB). 
The European Bifurcation Club (EBC) consen-
sus document recommends a single “provisional” 
stenting technique, although acknowledging that 
bifurcations with diffuse SB involvement often 
requires double stenting [2]. Several stent tech-
niques have been developed in order to tailor 
double stent deployment to the complex anatomy 
of the bifurcation. Hence, significantly higher risk 
of myocardial infarction and stent thrombosis have 
been associated with double when compared with 
single stenting [3].
In this scenario, the main issues to effectively 
guarantee optimal vessel patency are prevention of 
plaque shifting and careful carena reconstruction; 
further complexity may be due to calcification 
that increases the risk of SB occlusion or hampers 
crossability or adequate lesion dilatation [4].
Various strategies have been tested in order to 
prepare the plaque in the bifurcation and to reduce 
or displace the amount of calcium before stenting, 
and the inherent scientific literature presents 
a consistent controversy. The aim of this paper 
is to review current strategies adopted to modify 
calcific plaque before stent deployment in coronary 
bifurcations.
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Calcification at bifurcating lesions
When dealing with a bifurcation lesion, the first 
issue should be an assessment of the relevance of 
the SB; in this view, Kim et al. [5] clearly docu-
mented that a length ≥ 73 mm, not the diameter 
of the SB, identifies a vessel supplying a “signifi-
cant” portion of myocardium, notably a fractional 
myocardial mass ≥ 10%.
Hence, following a widely accepted classifica-
tion by Medina et al. [6], SB plaque involvement 
should be checked. The so called “true bifurca-
tions” define lesions where plaque enters the SB, 
namely Medina 1,1,1–1,0,1–0,1,1, although there is 
growing evidence that not the sole SB involvement, 
but SB lesion length > 9 mm is an independent 
predictor of adverse events [7]. 
The use of intravascular imaging is of great 
value to ascertain the distribution of the plaque, 
the true vessel size and the extent of calcium in 
bifurcating lesions, even beyond the bifurcation of 
the left main (LM) [8], that is currently the only 
site where guidelines recommend the use of intra-
vascular ultrasound (IVUS) [9]. 
Extensive calcification is the main determinant 
of balloon and stent underexpansion during PCI 
(Fig. 1) [10]. The sensitivity of intravascular imag-
ing is far higher than angiography in detecting coro-
nary calcifications, as angiography is able to detect 
a calcified plaque only for calcium angles almost 
> 100°, by either IVUS or optical coherence to-
mography (OCT). Nevertheless, all disagreement 
between the angiography and intravascular imaging 
is related to thin calcifications that have not been 
shown to affect stent expansion (Table 1) [4]. Even 
with the availability of newer drug-eluting stents 
(DES), patients with severely calcified lesions 
still have worse clinical outcomes compared with 
those without [11]. Clinical relevance of coronary 
calcification cannot be neglected, as treating stent 
underexpansion in a heavily calcified lesion is more 
difficult than preventing it [12]. However, although 
there is general agreement that the greater the arc 
length, or thickness of calcium, the greater the 
likelihood of stent underexpansion, there are no 
published cutoffs that can be used for recommend-
ing lesion modification prior to stent implantation 
or the need for high-pressure adjunctive balloon 
inflations afterward.
The presence of extensive calcification at 
the site of bifurcation evaluated by OCT portends 
a higher risk of occlusion of the side branch, as 
documented by Fuijino et al. [4]. In multivariate 
analysis, the presence of a calcified plaque in 
Figure 1. Coronary calcified bifurcating lesion. Diffuse calcifications of left anterior descending artery (LAD); 
A. Fluoroscopy view (arrows indicate calcifications) of LAD; B. Angiographic view; C. Fluoroscopy view of incomplete 
balloon expansion.
Table 1. Calcium quantification by imaging modality.
Angiography Radio-opacities before contrast injection noted with cardiac motion  
(moderate), or without cardiac motion (severe)
Optical coherence tomography Signal-poor with sharply delineated leading, quantified by thickness  
(mild < 0.5 mm; severe > 0.5–1 mm), area, and volume
Intravascular ultrasound Hyperechoic leading edge with acoustic shadowing, quantified mainly  
by angle (concentric if > 270°) and length
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the bifurcation segment of MV (odds ratio [OR]: 
12.32; 95% confidence interval [CI]: 2.58–58.83; 
p = 0.002) as assessed by OCT was the most 
relevant feature associated with SB deterioration, 
being bifurcation angle > 70° (OR: 11.83; 95% CI: 
2.00–70.02; p = 0.007) and baseline % diameter of 
stenosis (DS) of SB (OR 1.07; 95% CI: 1.02–1.13; 
p = 0.012) other independent predictors of SB 
deterioration, as assessed by angiography.
The mechanism of SB closure due to calcium 
has not been fully elucidated, but a higher risk 
of carina shift due to reduced compliance of the 
wall opposing the SB and a lower resistence en-
countered by the inflated balloon at the SB ostium 
could be a potential hypothesis. Carina is typically 
spared from atherosclerosis distribution owing to 
high local shear stress [13], but is the potential 
source of subsequent stent failure.  Careful lesion 
preparation might therefore “soften” the lesion and 
reduce the risk of plaque shift (Table 2).
Modifying balloons
The cutting balloon has been available for 
almost 30 years. It is a semi-compliant balloon 
with three thin sharp blades mounted on its body, 
designed to cut the continuity of fibrocalcific 
plaque once the pressure of the balloon forces 
them against the vessel wall, creating fissures on 
the plaque. 
The main drawback of these tools is their 
high rigidity that hinders system advancement and 
lesion negotiation through tortuous and calcified 
vessels [14]. Moreover, cutting balloon angioplasty 
showed a higher rate of coronary perforation (0.8% 
vs. 0%, p = 0.03) and had no advantages in terms 
of restenosis compared to balloon angioplasty 
(31% vs. 30%, p = NS) [15]. Therefore, after the 
first optimistic feasibility reports [16], scoring 
the plaque to facilitate stent deployment has been 
reported only in occasional cases for treatment of 
calcified bifurcations. This technology has recently 
undergone some important revisions: in the newer 
generation of cutting balloons (Wolverine™ Cutting 
Balloon, Boston Scientific, USA), the atherotome’s 
support thickness has been reduced, without affect-
ing the functional height of the blade, resulting in 
an overall smaller crossing profile and improved 
crossability.
The principle of using a “buddy wire” to fracture 
calcified plaque [17] promoted the development 
of the scoring balloon: wires apposed externally 
to the body of the balloon increase local punc-
tual pressure, achieving plaque fissuration [18]. 
Otsuka et al. [19] recently proposed that prolon- 
ged inflation might improve the success rate 
of these devices with a “creep phenomenon”: 
a sustained tensile load produces microcrack for-
mation and propagation leading to a phasic tissue 
elongation. 
Scoring balloons are available in two different 
families, the first one is engineered as a traditional 
balloon with three segments of wire apposed spi-
rally or linearly on the outer surface of the balloon; 
the second kind has only one external wire and is 
engineered as a rapid exchange balloon with a very 
short monorail involving only the tip of the balloon, 
thus allowing the guidewire to course along the 
balloon and to serve, together with the other, as 
a scoring wire. Scoring balloon, especially the latter 
has a better crossing profile than old generation 
cutting balloons but still has less deliverability than 
a standard balloon. Several reports suggest a very 
good success rate but many authors still consider 
these devices limited to a less-than-severely calci-
fied lesion.
Using a provisional approach with a scoring 
balloon for the SB and a DES for the MV in “true” 
bifurcation lesions yielded promising results in 
a single arm prospective study, with a rate of crosso-
ver to stent deployment in the SB as low as 11%, and 
a target lesion revascularization rate of 3.3% [20].
Atherectomy
Rotational atherectomy (RA) (Rotablator, 
Boston Scientific-Scimed Corporation, Natick, 
Massachusetts), firstly introduced more than 30 
years ago [21], is a plaque modification method 
achieved by a high-speed diamond chips-coated 
rotating burr that allows selective abrasion of 
calcified hard tissues. In the pre-stent era RA 
was conceived as a stand-alone approach to obtain 
plaque debulking in order to gain lumen diameter in 
a severely calcified lesion. It subsequently became 
evident that RA may offer its best contribution as 
a major “plaque modifier” for subsequent balloon 
angioplasty and stent implantation. Calcified ostial 
and bifurcating lesions were effectively treated by 
RA in the pre-stent era [22]. Its main effect is to 
restore adequate lumen by breaking the continuity 
of calcium plaque, increasing lesion “crossability” 
and making the artery more compliant to balloon 
dilatation.
Rotational atherectomy relies on two princi-
ples [23]:
 — “Differential cutting” defines the ability to se-
lectively ablate hard plaque components while 
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displacing and sparing soft tissues, that are 
deflected away. At rotational speeds > 60,000 
rpm the friction, which occurs when sliding 
surfaces are in contact, is virtually eliminated. 
The “differential cutting” should theoretically 
allow RA to accomplish a selective abrasion 
of plaque in the proximity of a branch, thus 
increasing the procedural success rate and re-
ducing the need for side-branch intervention.
 — “Orthogonal displacement of friction” refers 
to a change in effective longitudinal friction, 
which is almost eliminated, resulting in re-
duced surface drag and unimpeded advance-
ment of the burr in tortuous and diseased 
segments of the coronary tree.
Rotablator® advances over a guidewire (Ro-
tawire), is a 325 cm long and 0.009” thin shaft, with 
a 0.014” 2.2 cm long floppy spring tip, which has 
a lower performance in crossing lesions and tor-
tuosity than a traditional guidewire. Rotawire can 
therefore be positioned through a microcatheter 
after an exchange with a “workhorse” guidewire. 
Table 2. Features of the main plaque modifying devices.
Device Material Technical features Ref.
Focused force  
dilatation balloon  
(Scoreflex™)
Semi-compliant or non-compliant  
balloon
A nitinol integral wire (~0.011”)  
and the “conventional” guide wire act 
as two opposite scoring elements
Balloon size 2.0–4 mm
Working range 6–16 atm
Crossing profile 0.032” F
5F Guiding catheter compatible
Guide wire 0.014’’
[17]
Scoring balloon  
(Angiosculpt®)
Semi-compliant balloon
Nitinol-enhanced balloon deflation
Electropolished, rectangular, spiral  
scoring element (~0.005”)
Balloon size 2.0–3.5 mm
Working range 2–20 atm
Crossing profile 0.047” F
6F Guiding catheter
Guide wire 0.014’’
[17, 20]
Cutting balloon  
(Wolverine™)
Nylon non-compliant balloon
Microsurgical blade, called: “Ather-
otome” (functional height: ~0.005”)
Balloon size 2.0–4.0 mm
Working range 8–16 atm
Reduced crossing  
profile then Flexotome®
5F Guiding catheter compatible
[16]
Rotational atherectomy 
(Rotablator®)
Diamond-coated elliptical burr  
rotating up to 190,000 rpm
Multiple burrs size (1.25–> 2.5 mm)
RotaWire™ (330 cm, 0.014’’,  
extra support or floppy)
Catheter 6–10 F  
(according to the size burr)
[23]
Orbital atherectomy  
system  
(Diamondback 360®)
Eccentrically mounted diamond- 
-coated crown (1.25 mm) rotating up  
to 200,000 rpm
6F Guiding catheter
ViperWire Advance®   
(0.014’’)
[27, 28, 
29]
Intravascular lithotripsy  
(Shockwave®)
Semi-compliant balloon containing  
a series of unfocused, electrohydraulic 
lithotripsy emitters
Balloon size 2.5–4 mm
Inflated to 4 atm and  
administered 4 cycles of 10 s
Crossing profile 0.044’’
6F Guiding catheter
Guide wire 0.014’’
[36]
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The burr is mounted on a spiral drive shaft that is 
connected to an advancer and covered by a sheath. 
The burr’s passage through the lesion creates 
fragments with a diameter theoretically smaller 
than blood cells; such microparticles should easily 
cross microcirculation and then be eliminated by 
the reticuloendothelial system. Nevertheless, the 
no-reflow phenomenon has frequently been reported 
after RA-assisted PCI, and therefore the use of 
a flushing solution containing vasodilators such as 
calcium antagonists, nitrates or adenosine alone or 
in combination has been suggested [24]. A widely 
used solution to cool the Rotablator® turbine and to 
flush the coronary circulation from debris generated 
during the ablation is a saline solution with equal 
proportions of verapamil, nitrates, and heparin 
(5 mg/5 mg/5,000 U in 500 mL of saline). The use 
of the Rotablator® is technically demanding and is 
associated with a significant incidence of adverse 
events. Among the procedural complications burr’s 
lodging, coronary perforation, large dissection, 
acute thrombosis with abrupt coronary occlusion 
and atrioventricular-block have been reported. In 
order to minimize the complication rate, the EAPCI 
consensus document [25] recommends distal posi-
tioning of the Rotawire in order to have adequate 
support and stability and the use a rotational speed in 
the range of 135,000–180,000 rpm to obtain effective 
plaque modification, with a gentle picking to-and-fro 
movement of the burr, avoiding brisk deceleration 
(> 5,000 rpm) and to stop rotation when the burr 
is over the lesion to minimize the risk of lodgment. 
During RA procedures the increased quantity of 
injected contrast medium may cause deterioration 
of renal function. Therefore, all strategies useful to 
contain acute kidney injury should be applied [26], 
although there are no randomized trials exploring 
this issue.
Currently, as the role of RA has changed from 
debulking to plaque preparation, a burr-to-artery 
diameter ratio of 0.5–0.6 (smaller than previously 
recommended 0.7) should be targeted in order 
to balance efficacy in lesion ablation and risk of 
coronary wall damage. 
After several failures to cross the lesion, 
downsizing of the burr is recommended. In case 
the smallest burr does not pass, a change to a more 
supportive, or even a larger guiding catheter must 
be considered. 
More recently, the Diamondback 360®, a coro-
nary orbital atherectomy system (OAS) has be-
come available. Mechanism of OAS is a differential 
sanding to reduce plaque burden with a carbon-
coated crown (1.25 mm). Theoretically, softer tis-
sue flexes away from the crown while fibrotic tissue 
or arterial calcium is engaged. A drive shaft with 
an eccentrically mounted diamond-coated crown 
provides proximal and distal sanding; the crown’s 
orbital diameter expands radially via centrifugal 
force [27]. Operators can control the speed of rota-
tion, with a higher speed creating a larger sanding 
diameter by increasing lateral pressure. Pivotal 
trials have documented safety and feasibility of 
OAS in preparation of severely calcified plaques 
before stent deployment [28, 29], although clinical 
evidence is still limited.
The interest in calcified lesion preparation was 
recently revived in the Comparison of Strategies 
to Prepare Severely Calcified Coronary Lesions 
(PREPARE-CALC) trial, where modifying balloons 
(cutting or scoring) were compared with RA, in the 
setting of stable coronary artery disease. Bifurcat-
ing lesion were present in 42% of cases. The trial 
showed a clear superiority in terms of procedural 
success in the RA group (98% vs. 81%, p < 0.001), 
driven by a 20% of cross-over to RA, while, at 
9 months, mean in-stent late lumen loss was similar 
in the two groups, as well as stent thrombosis (0% 
in both groups) [30].
Plaque debulking in coronary bifurcation with 
any atherectomy device (both RA and OAS) may 
pose some technical challenges because of the need 
of single wire use, impeding the protection of side 
branches (Fig. 2). Reportedly, a tricky approach 
with a child-in-mother guiding catheter allowed 
RA with the use of multiple guidewires in order to 
protect side branches proximal to the target lesion 
and to gain more support [31]. 
As for calcified bifurcating lesions, there are 
several observational studies highlighting the 
safety and effectiveness of RA, that achieved 
a high (> 90%) success rate with a low rate of major 
adverse events (MACE < 5%) and the need for 
bailout side-branch stenting (< 20%) [32, 33]. Re-
cently, Chambers et al. [34], in a series of patients 
undergoing atherectomy with either OAS or RA for 
severely calcified plaques, documented similar low 
30-day MACE rates among patients with bifurca-
tion as compared with non-bifurcation lesions. OAS 
was associated with significantly shorter procedure 
and fluoroscopy time, as compared with RA.
Lithoplasty
Intravascular lithotripsy (IvL) is the most re-
cent tool for the treatment of calcified lesion after 
being introduced in peripheral vascular angioplasty. 
IvL consists of a balloon catheter that uses sonic 
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pulses to fracture calcified tissues with virtually no 
debris production. The concept of acoustic waves 
to selectively crack hard bodies has been employed 
in urology for decades. This approach aims to avoid 
the trauma produced by blades and burrs and their 
related risk, still offering an effective disruptive 
action on calcium (Fig. 3).
IvL device is composed of a 12 mm long 
balloon catheter with three emitters inside the 
balloon between two radiopaque markers; it has 
a profile smaller than other modifying balloons, 
quite comparable to a non-compliant balloon and is 
available in 7 sizes ranging from 2.5 to 4.0 mm. An 
electrical discharge at the emitters vaporizes the 
Figure 3. Coronary calcified bifurcating lesion treated by coronary lithotripsy. Long left anterior descending artery 
(LAD) lesion involving the bifurcation site of a large diagonal branch (Diag); A. Angiographic view; B. Intravascular 
ultrasound (IVUS) section at bifurcation site, with an eccentric calcific plaque (asterisks); C. IVUS section at mid LAD, 
with a concentric calcific plaque (“annular ring”); D, E. Intravascular lithotripsy (IvL) balloon inside of the lesions; 
F, G. IVUS section after IvL, showing effective disruption of the calcific plaques; H. Final angiographic view after LAD 
stenting.
Figure 2. Coronary calcified bifurcating lesion treated by rotablator. Diffuse calcified atherosclerosis of left anterior 
descending artery (LAD) resulting in severe stenosis involving the bifurcation site of a large diagonal branch (Diag); 
A. Angiographic view; B. Rotawire positioned distally in the main branch with Rotablator burr approaching the lesion; 
C. final result after provisional stenting.
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fluid generating a series of sonic pulses that propa-
gate and selectively interact with calcified plaques 
even in their inner adventitial layer. In the absence 
of any system mounted onto the balloon itself, the 
profile of IvL should guarantee better crossability 
than other modifying balloons, although in severely 
calcified lesions uncrossable by any balloon, atherec-
tomy seems to stand as a last resource. In another 
way, unlike RA, IvL can be used with more than 
a guidewire to protect side branches; its effect might 
theoretically extend to calcified side branches ostia 
and, reportedly, it can be used with the kissing bal-
loon technique because of the presumed ability of 
IvL to propagate across a second balloon. Moreover, 
IvL has been employed to fracture a calcified plaque 
outside an underexpanded stent, allowing appropri-
ate stent expansion at subsequent high-pressure 
dilatation [35]. An OCT study [36] demonstrated 
that vessel preparation with IvL led to an increase 
in minimum lumen area and a reduction in area 
stenosis, allowing stents to be delivered into all 
target lesions, with an efficacy proportional with 
calcification severity, with a very low complication 
rate (no perforation, nor slow/no flow phenomenon). 
The prospective, multicenter, single arm Study 
“Disrupt CAD II”, recently documented the safety 
and the effectiveness of IvL [37].
Conclusions
Percutaneous coronary intervention of a se-
verely calcified bifurcating stenosis is a challenge 
due to the inherent risks related to inadequate 
stent expansion and side branch compromise. 
Therefore, adequate lesion preparation with 
dedicated tools is often required. Modifying 
balloons are effective in lesion preparation, 
but their use is undermined by low crossabilty. 
Atherectomy, has been available for 30 years 
only as rotational, more recently it has evolved 
as orbital, allowing a high success rate, with an 
increased complication rate as a trade-off. IvL 
are now promising devices that obtain calcific 
plaque fragmentation with sonic pulses locally 
delivered, but the clinical translation of such 
benefit is still to be determined.
Here we propose a practical algorithm for the 
treatment of severely calcified bifurcating lesions 
(Fig. 4); in crossable lesions, modifying balloons, 
scoring better than cutting, can be the first choice 
and now IvL is extremely promising. In case of 
crossing failure, atherectomy still stands as the last 
resource [38], but it requires SB removal.
Conflict of interest: None declared
Figure 4. Proposed algorithm for the treatment of severely calcified bifurcating lesions; *Side branch longer than 73 mm, 
with a diameter ≥ 2 mm; GW — guidewire; MV — main vessel; SB — side branch; PCI-DES — percutaneous coronary 
intervention–drug-eluting stent.
Severely calcified bifurcating lesion*
Uncrossable Crossable
Undilatable
Atherectomy
PCI-DES
Lithopasty (if avail.)
Modyfing balloon
Double guidewire on MV and SB
SB guidewire removal
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